Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1997 1
2003 1
2010 1
2011 2
2012 1
2013 3
2014 1
2017 1
2018 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Platinum-Resistant Malignant Germ Cell Tumor"
Page 1
Therapeutic approaches for refractory germ cell cancer.
Oing C, Seidel C, Bokemeyer C. Oing C, et al. Expert Rev Anticancer Ther. 2018 Apr;18(4):389-397. doi: 10.1080/14737140.2018.1450630. Epub 2018 Mar 12. Expert Rev Anticancer Ther. 2018. PMID: 29516750 Review.
Most germ cell cancer patients with metastatic disease are cured by cisplatin-based combination chemotherapy. 30% of metastatic patients will develop relapse or progress despite adequate first-line treatment and will require salvage therapy, with about 10% of metast …
Most germ cell cancer patients with metastatic disease are cured by cisplatin-based combination chemotherapy. 30% of metastati …
Current controversies in the management of germ cell ovarian tumours.
Vazquez I, Rustin GJ. Vazquez I, et al. Curr Opin Oncol. 2013 Sep;25(5):539-45. doi: 10.1097/01.cco.0000432609.39293.77. Curr Opin Oncol. 2013. PMID: 23942298 Review.
PURPOSE OF REVIEW: Fewer than 70 new cases of malignant ovarian germ cell tumours (MOGCTs) are seen each year in the UK. Because of their rarity, no randomized trials have been reported and many of the advances in management have arisen from adopting practice …
PURPOSE OF REVIEW: Fewer than 70 new cases of malignant ovarian germ cell tumours (MOGCTs) are seen each year in the UK …
Nivolumab for the salvage treatment of desperate germ cell tumor: A case report.
Aksun MS, Ucgul E, Sahin TK, Guven DC, Aksoy S. Aksun MS, et al. J Oncol Pharm Pract. 2021 Sep;27(6):1516-1519. doi: 10.1177/1078155220977638. Epub 2020 Dec 6. J Oncol Pharm Pract. 2021. PMID: 33283628
INTRODUCTION: Testicular germ cell tumors (GCT) are the most common tumor in young men. Their distinctive feature is the exceptional response to platin based combination chemotherapy.Since the prognosis is poor in relapsed and refractory patients, the …
INTRODUCTION: Testicular germ cell tumors (GCT) are the most common tumor in young men. Their distinctive feature is th …
Advances in the chemotherapy of gynecologic cancer.
Neijt JP. Neijt JP. Curr Opin Oncol. 1994 Sep;6(5):531-8. doi: 10.1097/00001622-199409000-00015. Curr Opin Oncol. 1994. PMID: 7827159 Review.
The combination of paclitaxel and carboplatin is recognized as an alternative to the combination of cisplatin and paclitaxel, and is now under study to define its role in future treatment programs. Other new drugs have been recognized as active in platinum-resistant …
The combination of paclitaxel and carboplatin is recognized as an alternative to the combination of cisplatin and paclitaxel, and is now und …
Germ cell tumors: review of selected studies from 2002.
Hellerstedt BA, Pienta KJ. Hellerstedt BA, et al. Curr Opin Oncol. 2003 May;15(3):234-8. doi: 10.1097/00001622-200305000-00010. Curr Opin Oncol. 2003. PMID: 12778018 Review.
New chemotherapeutic options are available for patients with platinum-resistant disease, and stem cell transplant remains an area of active study....
New chemotherapeutic options are available for patients with platinum-resistant disease, and stem cell transplant remai …
Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
Nitzsche B, Gloesenkamp C, Schrader M, Hoffmann B, Zengerling F, Balabanov S, Honecker F, Höpfner M. Nitzsche B, et al. Br J Cancer. 2012 Nov 20;107(11):1853-63. doi: 10.1038/bjc.2012.481. Br J Cancer. 2012. PMID: 23169338 Free PMC article.
BACKGROUND: Resistance to cisplatin-based chemotherapy is associated with poor prognosis in testicular germ cell cancer, emphasising the need for new therapeutic approaches. ...In this study, we investigated the efficacy of these new compounds in platinum …
BACKGROUND: Resistance to cisplatin-based chemotherapy is associated with poor prognosis in testicular germ cell cancer …
Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
Fedyanin M, Tryakin A, Kanagavel D, Bulanov A, Burova A, Figurin K, Fainshtein I, Sergeev U, Zakharova T, Garin A, Tjulandin S. Fedyanin M, et al. Urol Oncol. 2013 May;31(4):499-504. doi: 10.1016/j.urolonc.2011.06.001. Epub 2011 Jul 30. Urol Oncol. 2013. PMID: 21803619
OBJECTIVES: Late relapses (>2 years) after completion of chemotherapy are rare and often platinum-resistant. There are limited data concerning late relapses in chemotherapy-naive patients with stage I germ cell tumors. ...METHODS AND MATERIALS: We a …
OBJECTIVES: Late relapses (>2 years) after completion of chemotherapy are rare and often platinum-resistant. There are limi …
Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes.
Necchi A, Nicolai N, Mariani L, Lo Vullo S, Giannatempo P, Raggi D, Farè E, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Milani A, Gianni AM, Salvioni R. Necchi A, et al. Clin Genitourin Cancer. 2014 Feb;12(1):63-69.e1. doi: 10.1016/j.clgc.2013.07.005. Epub 2013 Oct 23. Clin Genitourin Cancer. 2014. PMID: 24161525 Clinical Trial.
The Kaplan-Meier method was used for survival estimates, and multiple Cox regression models were used to analyze the prognostic factors. RESULTS: Seventy-five patients were treated from April 1999 to July 2011. ...
The Kaplan-Meier method was used for survival estimates, and multiple Cox regression models were used to analyze the prognostic facto …
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, Karlan BY, Taniguchi T, Swisher EM. Norquist B, et al. J Clin Oncol. 2011 Aug 1;29(22):3008-15. doi: 10.1200/JCO.2010.34.2980. Epub 2011 Jun 27. J Clin Oncol. 2011. PMID: 21709188 Free PMC article.
Thirteen (28.3%) of 46 (95% CI, 17.3% to 42.6%) recurrent carcinomas had a secondary mutation compared with two (3.1%) of 64 (95% CI, 1.0% to 10.7%) primary carcinomas (P = .0003, Fisher's exact test). Twelve (46.2%) of 26 (95% CI, 28.7% to 64.7%) platinum-resistant …
Thirteen (28.3%) of 46 (95% CI, 17.3% to 42.6%) recurrent carcinomas had a secondary mutation compared with two (3.1%) of 64 (95% CI, 1.0% t …
F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo.
Winer I, Wang S, Lee YE, Fan W, Gong Y, Burgos-Ojeda D, Spahlinger G, Kopelman R, Buckanovich RJ. Winer I, et al. Cancer Res. 2010 Nov 1;70(21):8674-83. doi: 10.1158/0008-5472.CAN-10-1917. Epub 2010 Oct 19. Cancer Res. 2010. PMID: 20959470 Free PMC article.
In vivo these nanoparticles bind primarily to tumor endothelial cells. Therapeutic studies in both flank and orthotopic i.p. murine ovarian tumor models, as well as human tumor xenograft models, show rapid tumor regression with treatment. ...Furthermor …
In vivo these nanoparticles bind primarily to tumor endothelial cells. Therapeutic studies in both flank and orthotopic i.p. murine o …
12 results